The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

Sweden has surpassed the UNAIDS 95-95-95 targets, with reduced HIV incidence and a steady increase in diagnosed and treated ...

In this cross-sectional study, researchers explored immune activation as a possible mechanism for this seemingly paradoxical response to HIV infection. CD4-cell counts and T-cell activation levels ...

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

In the human immune system, γδ T cells play a crucial role in defense against foreign pathogens and regulation of autoimmune responses. These cells act as a bridge between innate and adaptive immunity ...

数据显示，在2023年，全球共有近4000万艾滋病患者，其中有约130万新确诊患者，63万人因艾滋病相关疾病死亡。艾滋病是由于HIV病毒感染造成的传染性疾病。现代抗病毒药物的发展和抗病毒“鸡尾酒疗法”的兴起，已经让HIV感染患者能够长期控制病情，并且 ...

Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational ...

Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...

Nomonde Ngema, 21, who was born with HIV, not only tackles the stigma on TikTok by sharing her journey, she also takes on ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...